GB856413A - New lipo-polysaccharides of bacterial origin and process for prearing same - Google Patents
New lipo-polysaccharides of bacterial origin and process for prearing sameInfo
- Publication number
- GB856413A GB856413A GB7814/57A GB781457A GB856413A GB 856413 A GB856413 A GB 856413A GB 7814/57 A GB7814/57 A GB 7814/57A GB 781457 A GB781457 A GB 781457A GB 856413 A GB856413 A GB 856413A
- Authority
- GB
- United Kingdom
- Prior art keywords
- lipo
- polysaccharides
- dialysing
- ethanol
- radical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000002158 endotoxin Substances 0.000 title abstract 7
- 230000001580 bacterial effect Effects 0.000 title 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 8
- 239000000463 material Substances 0.000 abstract 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 abstract 2
- 241000894006 Bacteria Species 0.000 abstract 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 abstract 2
- 150000007933 aliphatic carboxylic acids Chemical class 0.000 abstract 2
- 239000008346 aqueous phase Substances 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000002609 medium Substances 0.000 abstract 2
- 235000015097 nutrients Nutrition 0.000 abstract 2
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 2
- 230000001376 precipitating effect Effects 0.000 abstract 2
- 238000002360 preparation method Methods 0.000 abstract 2
- 241000219470 Mirabilis Species 0.000 abstract 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 abstract 1
- 241000588770 Proteus mirabilis Species 0.000 abstract 1
- 241000588767 Proteus vulgaris Species 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 230000002402 anti-lipaemic effect Effects 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 239000007864 aqueous solution Substances 0.000 abstract 1
- 239000000872 buffer Substances 0.000 abstract 1
- 239000002775 capsule Substances 0.000 abstract 1
- 239000006071 cream Substances 0.000 abstract 1
- 239000008298 dragée Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 239000003995 emulsifying agent Substances 0.000 abstract 1
- 239000000839 emulsion Substances 0.000 abstract 1
- 239000001963 growth medium Substances 0.000 abstract 1
- 239000002198 insoluble material Substances 0.000 abstract 1
- 229920006008 lipopolysaccharide Polymers 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000002674 ointment Substances 0.000 abstract 1
- 238000007911 parenteral administration Methods 0.000 abstract 1
- 230000001717 pathogenic effect Effects 0.000 abstract 1
- 239000011049 pearl Substances 0.000 abstract 1
- KSSNXJHPEFVKHY-UHFFFAOYSA-N phenol;hydrate Chemical compound O.OC1=CC=CC=C1 KSSNXJHPEFVKHY-UHFFFAOYSA-N 0.000 abstract 1
- 229910052698 phosphorus Inorganic materials 0.000 abstract 1
- 239000011574 phosphorus Substances 0.000 abstract 1
- 239000003755 preservative agent Substances 0.000 abstract 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000004062 sedimentation Methods 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 239000000243 solution Substances 0.000 abstract 1
- 241000894007 species Species 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
- 230000000087 stabilizing effect Effects 0.000 abstract 1
- 239000000725 suspension Substances 0.000 abstract 1
- 239000003826 tablet Substances 0.000 abstract 1
- 230000000699 topical effect Effects 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
- 238000009736 wetting Methods 0.000 abstract 1
- 239000000080 wetting agent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention comprises lipo-polysaccharides obtainable by cultivating bacteria of the species Proteus vulgaris or mirabilis aerobically on a fully synthetic nutrient medium and either (a) dialysing the separated cell material, treating the non-dialysable material with a phenol-water mixture at an elevated temperature, extracting the aqueous phase with ether, and dialysing the aqueous phase, if desired after precipitating its valuable content with ethanol, and, if desired, purifying the material; or (b) dialysing the culture medium freed from cell material, precipitating the aqueous solution freed from insoluble material with ethanol, dialysing the precipitated material and fractionating it with ethanol, acetone or quaternary ammonium compounds containing a high molecular weight aliphatic radical and being soluble in water and ethanol, and, if desired, purifying the material. The acylated lipo-polysaccharides derived by treatment of the above products with acylating agents introducing the radical of aliphatic carboxylic acids having 1-4 carbon atoms, are also novel compounds. The lipopolysaccharides are of high molecular weight, possess no substantial antigenic and pathogenic activity but are active in leucocyte emigration tests and show antilipemic activity. They have a sugar content of at least 20%, phosphorus content of at least 1,7% and a sedimentation constant of 1,9 X 10-13. The novel compounds are used in pharmaceutical preparations (see Group VI).ALSO:Pharmaceutical preparations for topical, enteral or parenteral administration contain one or more lipo-polysaccharides obtainable by cultivating bacteria of the species Protens vulgaris or mirabilis aerobically on a fully synthetic nutrient medium, and acylated products derivable from said lipo-polysaccharides by treatment with acylating agents introducing the radical of an aliphatic carboxylic acid having 1 to 4 carbon atoms, (for preparation see Group IV(a)), in admixture with solid or liquid pharmaceutical carriers. The preparations may be used in the form of creams, salves, tablets, dragees, capsules, pearls, solutions, suspensions, or emulsions. They may be sterilized and/or contain preserving, stabilizing, wetting or emulsifying agents, salts, buffers or other therapeutically active substances. They contain the lipo-polysaccharides in an amount of 0,001g -100g per dosage unit.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH856413X | 1956-03-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB856413A true GB856413A (en) | 1960-12-14 |
Family
ID=4542720
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB7814/57A Expired GB856413A (en) | 1956-03-08 | 1957-03-08 | New lipo-polysaccharides of bacterial origin and process for prearing same |
Country Status (1)
| Country | Link |
|---|---|
| GB (1) | GB856413A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2123562A1 (en) * | 1968-12-16 | 1972-09-08 | Abbott Lab | |
| FR2648350A1 (en) * | 1989-06-20 | 1990-12-21 | Roussel Uclaf | USE OF LIPOPOLYSACCHARIDES EXTRACTED FROM BACTERIA GRAM (-) FOR THE MANUFACTURE OF A MEDICAMENT FACILITATING THE HEALING OF THE SKIN |
-
1957
- 1957-03-08 GB GB7814/57A patent/GB856413A/en not_active Expired
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2123562A1 (en) * | 1968-12-16 | 1972-09-08 | Abbott Lab | |
| FR2648350A1 (en) * | 1989-06-20 | 1990-12-21 | Roussel Uclaf | USE OF LIPOPOLYSACCHARIDES EXTRACTED FROM BACTERIA GRAM (-) FOR THE MANUFACTURE OF A MEDICAMENT FACILITATING THE HEALING OF THE SKIN |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Spencer et al. | Quantitative differences and gene dosage in the human red cell acid phosphatase polymorphism | |
| US2563794A (en) | Vitamin b12 | |
| Stone et al. | Cytogenetic effects of cyclamates on human cells in vitro | |
| JPS54147997A (en) | Novel hyaluronidase bmp-8231 and its preparation | |
| McIlwain et al. | Glutamine and the growth of Streptococcus haemolyticus | |
| Stich et al. | The effect of ribonuclease on protein synthesis in nucleated and enucleated fragments of Acetabularia | |
| Hicks et al. | Adrenal cortical hormones and the formation of histamine and 5-hydroxytryptamine | |
| Smith et al. | The chemical basis of the virulence of Bacillus anthracis VII. Two components of the anthrax toxin: their relationship to known immunising aggressins | |
| DE2146400B2 (en) | New biosynthetic active ingredient, process for its production and pharmaceutical preparations containing this active ingredient | |
| GB856413A (en) | New lipo-polysaccharides of bacterial origin and process for prearing same | |
| Dewey | Biochemical factors in the maximal growth of Tetrahymena | |
| Ishizuka et al. | Antitumor activities of formycin and labilomycin | |
| CN101215283A (en) | Shuangkoushan ketone compound Secalonic acid A and its preparation method and application in the preparation of neuron cell protection drugs | |
| Koser et al. | Comparative Activity of Nicotinic Acid and Nicotinamide as Growth Factors for Microörganisms. | |
| Klein et al. | Sterile induction of crown-gall tumors on carrot tissues in vitro | |
| Rogers et al. | The recognition of material present in horse muscle affecting the formation of α-toxin by a strain of Clostridium welchii | |
| Bain | Vaccination against haemorrhagic septicaemia of bovines | |
| US3000793A (en) | Production of cobalamins | |
| Mizoguchi et al. | Studies on the Biosynthesis of Macrophage Migration Inhibitory Factor in Delayed Hypersensitivity: I. Effects of Inhibitors of Nucleic Acid and Protein Synthesis on the Production of Macrophage Migration Inhibitory Factor | |
| US2601350A (en) | Hydrolysis of beta lactam linkage by penicillinase | |
| US2609325A (en) | Recovery of vitamin b12 from liver | |
| US2695862A (en) | Process for obtaining vitamin b12 | |
| DE3485773T2 (en) | MACROMOLECULES EXTRACTED FROM CULTIVATED MESENCHYM CELLS FOR THE TREATMENT OF DEGENERATIVE DISEASES. | |
| GB856414A (en) | Anti-allergic and anti-viral substances prepared from bacterial cultures | |
| Booyens, J. & Koenig | The effect of dietary supplementation with gamma-linolenic acid on the growth of induced tumours in rats |